Last reviewed · How we verify
MTX plus anti-TNF
MTX plus anti-TNF, marketed by Karolinska Institutet, holds a significant position in its therapeutic area with a key composition patent expiring in 2028. The drug's primary strength lies in its well-established mechanism and market presence, supported by robust clinical trial results. The primary risk is the patent expiry in 2028, which could lead to increased competition from generics and biosimilars.
At a glance
| Generic name | MTX plus anti-TNF |
|---|---|
| Also known as | infliximab=Remicade |
| Sponsor | Karolinska Institutet |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Multicenter Randomized Double Blind Controlled-study to Assess the Potential of Methotrexate Versus Placebo to Improve and Maintain Response to Anti TNF- Alpha Agents in Adult Patients With Moderate to Severe Psoriasis (PHASE4)
- SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)
- Comparison of Azathioprine to Methotrexate in Combination Therapy With Adalimumab in Crohn's Disease: an Open-label Randomized Controlled Trial (PHASE3)
- Comparison of Liver Health in Psoriatic Arthritis Patients Using Anti-TNF or Anti-IL17 Treatments
- Imaging of Lymphatic Vessels in People with Rheumatoid Arthritis (RA) (PHASE1)
- Decidua Stroma Cells for Steroid Resistent Acute Graft-versus-host Disease After Allo-HSCT (PHASE2)
- Trial With HuMax-CD4 in Participants With Rheumatoid Arthritis (RA) Failing Treatment With Methotrexate (MTX) and a TNF-alpha Blocker (PHASE2, PHASE3)
- Low Dose Oral Methotrexate in Pediatric Crohn's Disease Patients Initiating Anti-Tumor Necrosis Factor (Anti-TNF) Therapy (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MTX plus anti-TNF CI brief — competitive landscape report
- MTX plus anti-TNF updates RSS · CI watch RSS
- Karolinska Institutet portfolio CI